Home/Cytoki Pharma/Dorte Waaben

DW

Dorte Waaben

Head of CMC

Therapeutic Areas

Metabolic Disease Obesity Type 2 Diabetes Inflammatory Bowel Disease

Cytoki Pharma Pipeline

Drug	Indication	Phase
CK-0045	Obesity and Type 2 Diabetes	Phase 2

Leadership Team at Cytoki Pharma

Rasmus Jorgensen

Anne Louise Kjølbye

Chief Development Officer

Martijn van de Bunt

Chief Scientific Officer

Chief Business Officer

Karsten Skydsgaard

Head of Non-Clinical Development

Christian Friis

Clinical Project Leader

View full Cytoki Pharma profile